Evidence map›Paper›PMID 28126496›Full record

ArticleNeuropharmacology2017

Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell.

Elizabeth J Crofton, Miroslav N Nenov, Yafang Zhang, Federico Scala, Sean A Page, David L McCue, Dingge Li, Jonathan D Hommel, Fernanda Laezza, Thomas A Green

Abstract read
In one paragraph

Article in Neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Targeting the Limbic System: Insights into Its Involvement in Tinnitus.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Glycogen Synthase Kinase 3: Ion Channels, Plasticity, and Diseases.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Elizabeth J CroftonCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Miroslav N NenovCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Yafang ZhangCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Federico ScalaCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA; Biophysics Graduate Program, Institute of Human Physiology, Universita Cattolica, Rome, Italy.
Sean A PageCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
David L McCueCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Dingge LiCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Jonathan D HommelCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Fernanda LaezzaCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA.
Thomas A GreenCenter for Addiction Research, The University of Texas Medical Branch, Galveston, TX, USA; Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX, USA. Electronic address: tom.green@utmb.edu.
The University of Texas Medical Branch at Galveston · USUniversità Cattolica del Sacro Cuore · IT

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2003 to 2026
$46.3M
Neurpsychopharmacology-Multidisciplinary TrainingT32AA007456 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 1985 to 2026
$13.4M
MARC PROGRAM FOR CALIFORNIA STATE UNIVERSITY, FULLERTONT34GM008612 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI COHEN, AMYBETH · 1996 to 2021
$7.4M
Translational Explorations in Substance Use DisordersT32DA007287 · NIDA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Kathryn A. Cunningham, Jonathan Dean Hommel · 1994 to 2026
$4.7M
Validation of FGF14 as a New Molecular Target of GSK3R01MH095995 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LAEZZA, FERNANDA · 2012 to 2016
$1.9M
Molecular Mechanisms of Environmental EnrichmentR01DA029091 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GREEN, THOMAS ARTHUR · 2011 to 2015
$1.8M
NIAAA NIH HHS P60 AA006420NIAAA NIH HHS T32 AA007456NIDA NIH HHS R01 DA029091NIDA NIH HHS T32 DA007287NIGMS NIH HHS T34 GM008612NIMH NIH HHS R01 MH095995
6 · The paper itself

Abstract

Psychiatric disorders such as anxiety, depression and addiction are often comorbid brain pathologies thought to share common mechanistic biology. As part of the cortico-limbic circuit, the nucleus accumbens shell (NAcSh) plays a fundamental role in integrating information in the circuit, such that modulation of NAcSh circuitry alters anxiety, depression, and addiction-related behaviors. Intracellular kinase cascades in the NAcSh have proven important mediators of behavior. To investigate glycogen-synthase kinase 3 (GSK3) beta signaling in the NAcSh in vivo we knocked down GSK3beta expression with a novel adeno-associated viral vector (AAV2) and assessed changes in anxiety- and depression-like behavior and cocaine self-administration in GSK3beta knockdown rats. GSK3beta knockdown reduced anxiety-like behavior while increasing depression-like behavior and cocaine self-administration. Correlative electrophysiological recordings in acute brain slices were used to assess the effect of AAV-shGSK3beta on spontaneous firing and intrinsic excitability of tonically active interneurons (TANs), cells required for input and output signal integration in the NAcSh and for processing reward-related behaviors. Loose-patch recordings showed that TANs transduced by AAV-shGSK3beta exhibited reduction in tonic firing and increased spike half width. When assessed by whole-cell patch clamp recordings these changes were mirrored by reduction in action potential firing and accompanied by decreased hyperpolarization-induced depolarizing sag potentials, increased action potential current threshold, and decreased maximum rise time. These results suggest that silencing of GSK3beta in the NAcSh increases depression- and addiction-related behavior, possibly by decreasing intrinsic excitability of TANs. However, this study does not rule out contributions from other neuronal sub-types.

Indexed as

Action PotentialsAnimalsAnxietyBehavior, AddictiveBehavior, AnimalCocaineDepressionGene Knockdown TechniquesGlycogen Synthase Kinase 3 betaInterneuronsMaleNucleus AccumbensRatsSelf AdministrationCocaineGlycogen Synthase Kinase 3 betaCocaineDepressionDrug addictionNucleus accumbensSelf-administrationTonically active neurons

Identifiers

PMID28126496
PMCPMC5386787
OpenAlexW2582255964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.